Tranche 1 and 2 $7m capital raising from some of the most sophisticated biotech institutional investors in Australia completed . Current share price of 8.6c is a bargain imo considering the clinical-stage pipeline with three Phase 1b/2 clinical trials in breast cancer, ovarian cancer and acute myeloid leukemia (AML) at prestigious US medical institutions.
Remaining $3.4m raising from rights issue expected to be filled next week. Will be taking up my lot and some extra's.
PTX Price at posting:
8.6¢ Sentiment: Buy Disclosure: Held
